Foghorn Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Okay. We will continue with the next session, which is Foghorn Therapeutics. I'm Paul Choi, and I cover the SMID-cap biotech sector. It's my pleasure to have Adrian Gottschalk to my immediate left here. Maybe what we'll do is what we've done in prior sessions.
And maybe we'll let Adrian sort of describe what are Foghorn's strategic priorities for the remainder of '26 and going into '27, and then we'll go into Q&A.
Sounds great, Paul. Thanks for having me. Thanks to everyone for being here today. Yes, look, I think next up and most importantly, as we think about 2026 is our FHD-909 program. This is the selective SMARCA2 inhibitor molecule that is partnered with our colleagues at Eli Lilly in a 50-50 strategic collaboration with them.
So, our guidance hasn't changed over the course of the last six or so months. I anticipate that sometime over the course of the summer, we'll be in a position where the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
